Arbutus Deferred Long Term Liab from 2010 to 2024
| ABUS Stock | USD 3.47 0.06 1.76% |
Deferred Long Term Liabilities | First Reported 2000-03-31 | Previous Quarter 10.6 M | Current Value 3.3 M | Quarterly Volatility 38.4 M |
Check Arbutus Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arbutus Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 701.5 K or Selling General Administrative of 12.2 M, as well as many indicators such as Price To Sales Ratio of 13.01, Dividend Yield of 0.0529 or PTB Ratio of 3.72. Arbutus financial statements analysis is a perfect complement when working with Arbutus Biopharma Valuation or Volatility modules.
Arbutus | Deferred Long Term Liab |
Latest Arbutus Biopharma's Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Arbutus Biopharma Corp over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Arbutus Biopharma's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arbutus Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Arbutus Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 20,696,281 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 175.43 | |
| Mean Deviation | 19,520,992 | |
| Median | 13,306,000 | |
| Standard Deviation | 36,307,354 | |
| Sample Variance | 1318.2T | |
| Range | 146.5M | |
| R-Value | 0.01 | |
| Mean Square Error | 1419.5T | |
| R-Squared | 0.000077 | |
| Significance | 0.98 | |
| Slope | 71,173 | |
| Total Sum of Squares | 18455.1T |
Arbutus Deferred Long Term Liab History
About Arbutus Biopharma Financial Statements
Arbutus Biopharma shareholders use historical fundamental indicators, such as Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although Arbutus Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Arbutus Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Arbutus Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 15.3 M | 13.2 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.